[6-K] Intercure Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

InterCure Ltd. reported that it will hold its Annual General Meeting of Shareholders on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of its legal counsel in Tel Aviv, Israel. The company is providing shareholders with a Notice and Proxy Statement describing the proposals to be voted on and the procedures for voting in person or by proxy, together with a Proxy Card that enables holders of ordinary shares to vote without attending the meeting. These materials are furnished as exhibits to the report so shareholders can review the agenda and participate in the decision-making process for the company.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On November 25, 2025, InterCure Ltd. (the “Company”) announced that it will hold its Annual General Meeting of Shareholders (the “Meeting”) on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6^th floor, Ramat Hachayal, Tel Aviv, Israel. In connection with the Meeting, the Company furnishes the following documents:

	1.	A copy of the Notice and Proxy Statement with respect to the Meeting describing the proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting, attached hereto as Exhibit 99.1; and
	2.	A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the Meeting without attending in person, attached hereto as Exhibit 99.2.

Exhibit No.
99.1		Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders.
99.2		Proxy Card for holders of ordinary shares with respect to the Company’s Annual General Meeting of Shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: November 25, 2025	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer

FAQ

What did InterCure Ltd. (INCR) announce in this Form 6-K?

InterCure Ltd. announced that it will hold its Annual General Meeting of Shareholders and is furnishing a Notice and Proxy Statement and a Proxy Card related to that meeting.

When and where is InterCure Ltd.'s 2025 Annual General Meeting of Shareholders?

The meeting is scheduled for December 30, 2025 at 4:00 p.m. (Israel time) at the offices of Amit, Pollak, Matalon & Co., APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.

What documents did InterCure Ltd. provide in connection with the Annual General Meeting?

The company furnished a Notice and Proxy Statement as Exhibit 99.1 and a Proxy Card for holders of ordinary shares as Exhibit 99.2.

How can InterCure (INCR) shareholders vote if they do not attend the meeting in person?

Holders of ordinary shares may vote without attending in person by using the Proxy Card provided as Exhibit 99.2, following the procedures described in the Notice and Proxy Statement.

What information is contained in InterCure Ltd.'s Notice and Proxy Statement?

The Notice and Proxy Statement describe the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy, and other details related to the Annual General Meeting.

Who signed the Form 6-K on behalf of InterCure Ltd.?

The report was signed on behalf of InterCure Ltd. by Amos Cohen, Chief Financial Officer.